Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Clonazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 5/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 5/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 5/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 5/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 4/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 4/20 | 1.00 |
| ▸ | GABRP known ✓ | O00591 | 3/20 | 1.00 |
| ▸ | GABRD known ✓ | O14764 | 3/20 | 1.00 |
| ▸ | GABRB1 known ✓ | P18505 | 3/20 | 1.00 |
| ▸ | GABRA4 known ✓ | P48169 | 3/20 | 1.00 |
| ▸ | GABRE known ✓ | P78334 | 3/20 | 1.00 |
| ▸ | GABRA6 known ✓ | Q16445 | 3/20 | 1.00 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 3/20 | 1.00 |
| ▸ | GABRG3 known ✓ | Q99928 | 3/20 | 1.00 |
| ▸ | GABRQ known ✓ | Q9UN88 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clonazepam SCHEMBL38899 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL5501860 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL13747803 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL13746712 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29361251 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29743048 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL28390843 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL31321724 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL9834407 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL20771795 | 0.98 | GABRA1 (0.96) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115938477-A | Method, device, equipment and storage medium for measuring multi-character breeding value | 四川新希望六和猪育种科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-114172546-B | Multi-parameter iterative estimation method in RIS auxiliary MIMO system | 中国传媒大学 | 2022-11-01 | — | — | CN | claimed |
| CN-114948852-A | Microneedle system for diagnosis and treatment of brain diseases and preparation method thereof | 深圳先进技术研究院 | 2022-08-30 | — | — | CN | claimed |
| WO-2026102419-A1 | ACCELERATED BREEDING AND IMPROVED TRAINING DATA | MONSANTO TECHNOLOGY LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260076316-A1 | BENTONITE-CONTAINING HYDROGELS AND RELATED METHODS | VELOCIGRO INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3464610-B1 | METHODS FOR ANALYSING MICROBIOTA | UNIV OTTAWA (CA) | 2026-03-04 | — | — | EP | disclosed |
| US-20250361531-A1 | MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS | AGAIN BIO APS (DK) | 2025-11-27 | — | — | US | disclosed |
| US-20250277991-A1 | DEVICES AND RELATED METHODS FOR TREATMENT OF BRAIN DISORDERS AND STIMULATING CHANGE IN PSYCHOLOGICAL STATE | SCHIFFER FREDRIC (US) | 2025-09-04 | — | — | US | disclosed |
| EP-4580400-A1 | HORTICULTURAL HYDROGELS | VelociGro Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250204340-A1 | HORTICULTURAL HYDROGELS | VELOCIGRO INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250194470-A1 | METHOD TO PRODUCE SEEDS RAPIDLY THROUGH ASEXUAL PROPAGATION OF CUTTINGS IN LEGUMES | CONFLUENCE GENETICS, LLC | 2025-06-19 | — | — | US | disclosed |
| EP-3324975-B1 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | HSU JOHN (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114438002-A | Cell for expressing phosphotransferase and non-ribosomal peptide synthetase and application thereof | 浙江工业大学 | 2022-05-06 | — | — | CN | disclosed |
| CN-114391019-A | Compositions and methods for treating CNS disorders | 萨奇治疗股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114350692-A | Method for preparing decarboxylated carnosine by whole-cell catalysis | 浙江工业大学 | 2022-04-15 | — | — | CN | disclosed |
| WO-2022076699-A2 | GRAFTED PLANT FOR DELIVERY OF GENOME EDITING REAGENTS | CALYXT, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220047561-A1 | SALTS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2022-02-17 | — | — | US | disclosed |
| WO-2022031716-A1 | ENHANCED TREATMENT OF BRAIN DISORDERS UTILIZING COORDINATED NEGATIVE SUPPRESSIVE STIMULATION AND RELATED DEVICES DESIGNED TO ACHIEVE TREATMENT | Mindlight, LLC (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20220033395-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220032084-A1 | ENHANCED TREATMENT OF BRAIN DISORDERS UTILIZING COORDINATED NEGATIVE SUPPRESSIVE STIMULATION AND RELATED DEVICES DESIGNED TO ACHIEVE TREATMENT | SCHIFFER FREDRIC (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047561-A1 | SALTS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF | TST, RIMKLA, PSPH | GABRA1 248/4885GABRA5 709/4885GABRA3 473/4885 |
| US-20260076316-A1 | BENTONITE-CONTAINING HYDROGELS AND RELATED METHODS | PWWP2B, CD44, CHIA | GABRA1 4484/4885GABRA5 4637/4885GABRA3 4437/4885 |
| US-20250361531-A1 | MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS | HSD17B10, HSD17B12, HADHB | GABRA1 489/4885GABRA5 586/4885GABRA3 507/4885 |
| US-20220033395-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | GABRA1 88/4885GABRA5 154/4885GABRA3 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.